US Patent

US8715724 — Tabletting process

Formulation · Assigned to Mayne Pharma International Pty Ltd · Expires 2028-02-03 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a process for producing a compressed solid dosage form, such as a tablet, containing an active ingredient like doxycycline hyclate.

USPTO Abstract

A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with an anti-static agent and compressed with suitable excipients to form the compressed solid dosage form. Preferred anti static agents are starch, microcrystalline cellulose, kaolin, bentonite, silicates, silicon dioxide, cellulose, stearic acid, sodium stearyl fumarate and glyceryl behenate.

Drugs covered by this patent

Patent Metadata

Patent number
US8715724
Jurisdiction
US
Classification
Formulation
Expires
2028-02-03
Drug substance claim
No
Drug product claim
Yes
Assignee
Mayne Pharma International Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.